CommercialCoverageMedium impact
Genetic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer (2.04.151)
Blue Shield of California·CA · Oncology, Pathology, Hematology·Genetic Testing
Effective date
Jun 1, 2026
We identified it
May 1, 2026
Summary
Blue Shield of California updated their genetic biomarker testing policy for advanced cancer, establishing specific coverage criteria for various genetic tests including ALK, BRAF, BRCA1/2, EGFR, and other biomarkers used to select targeted cancer therapies. The policy specifies when these tests are considered medically necessary based on cancer type, stage, and intended treatment.
Action Required
Before June 1, 2026: Billing and clinical teams must review and update prior authorization processes for genetic biomarker testing claims to ensure all specified criteria are met and documented. Update encounter forms and EMR templates to capture required cancer staging, prior treatments, and intended targeted therapy information. Claims not meeting the specific policy criteria will likely be denied.